Project Coordinator: Jean-Pierre Van Geertruyden
Institution: University of Antwerp (Belgium)
Target disease: Malaria
African countries involved: Burkina Faso and Uganda
Budget: € 777,910
Duration of the project: September 2011-June 2013

The study will assess the efficacy of quinine versus, amodiaquine-artesunate (ASAQ) or artemether–lumefantrine (AL) as rescue treatment. It will either accept the re-use of ASAQ or AL respectively as rescue treatment or provide strong evidence against this common practice. The need to provide the policy makers with reliable information on the appropriate rescue therapy is obvious. Evaluation of the best approach to retreat patients with recurrent malaria following ACT therapy is an important research area that will be addressed in this study. The main goal is to identify if first line artemisinin-combination therapy (ACT) can be safely and efficaciously used to retreat children with recurrent malaria occurring beyond 14 days after initial treatment and consequently preserve quinine for severe malaria treatment.